FDA Approves VIGABATRIN — Aurobindo Pharma Limited

# FDA Approves Aurobindo Pharma's Generic Vigabatrin, Expanding Treatment Options for Seizure Disorders The FDA has approved Aurobindo Pharma Limited's generic formulation of vigabatrin (ANDA215601), an oral antiepileptic medication, potentially increasing market competition and improving patient access to this specialized seizure treatment. The approval could enhance Aurobindo's position in the anticonvulsant market while providing physicians with additional generic alternatives for managing infantile spasms and refractory focal seizures.